Cerevel Therapeutics Holdings (STU:673) Ending Cash Position : €296.60 Mil (As of Mar. 2024)

View and export this data going back to 2022. Start your Free Trial

What is Cerevel Therapeutics Holdings Ending Cash Position?

Cerevel Therapeutics Holdings's Ending Cash Position for the quarter that ended in Mar. 2024 was €296.60 Mil.

Cerevel Therapeutics Holdings's quarterly Ending Cash Position increased from Sep. 2023 (€147.75 Mil) to Dec. 2023 (€383.70 Mil) but then declined from Dec. 2023 (€383.70 Mil) to Mar. 2024 (€296.60 Mil).

Cerevel Therapeutics Holdings's annual Ending Cash Position declined from Dec. 2021 (€174.54 Mil) to Dec. 2022 (€130.64 Mil) but then increased from Dec. 2022 (€130.64 Mil) to Dec. 2023 (€383.70 Mil).

Cerevel Therapeutics Holdings Ending Cash Position Historical Data

The historical data trend for Cerevel Therapeutics Holdings's Ending Cash Position can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Cerevel Therapeutics Holdings Ending Cash Position Chart

Cerevel Therapeutics Holdings Annual Data

Trend

Dec19

Dec20

Dec21

Dec22

Dec23

Ending Cash Position

75.31

318.79

174.54

130.64

383.70

Cerevel Therapeutics Holdings Quarterly Data
	Dec19	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23	Mar24
Ending Cash Position	Get a 7-Day Free Trial													145.41	164.04	147.75	383.70	296.60

Cerevel Therapeutics Holdings Ending Cash Position Calculation

Ending Cash Position is the cash and cash equivalents balance at the end of the accounting period, as indicated on the Cash Flow statement. It is equal to the Beginning Cash Position plus the Net Change in Cash.

Cerevel Therapeutics Holdings's Ending Cash Position for the fiscal year that ended in Dec. 2023 is calculated as

Ending Cash Position	=	Beginning Cash Position	+	Net Change in Cash
	=	126.902	+	256.794
	=	383.70

Cerevel Therapeutics Holdings's Ending Cash Position for the quarter that ended in Mar. 2024 is calculated as

Ending Cash Position	=	Beginning Cash Position	+	Net Change in Cash
	=	384.95	+	-88.346
	=	296.60

Cerevel Therapeutics Holdings Ending Cash Position Related Terms

Thank you for viewing the detailed overview of Cerevel Therapeutics Holdings's Ending Cash Position provided by GuruFocus.com. Please click on the following links to see related term pages.

Cerevel Therapeutics Holdings (STU:673) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Cerevel Therapeutics Holdings Inc (STU:673) » Definitions » Ending Cash Position

Comparable Companies

Traded in Other Exchanges

CERE:USA

Address

222 Jacobs Street, Suite 200, Cambridge, MA, USA, 02141

Website

https://www.cerevel.com

Cerevel Therapeutics Holdings Inc is dedicated to unraveling the mysteries of the brain to treat neuroscience diseases. The company is tackling neuroscience diseases with a differentiated approach that combines expertise in neurocircuitry with a focus on receptor selectivity. It has a diversified pipeline comprising five clinical-stage investigational therapies and several preclinical compounds with the potential to treat a range of neuroscience diseases, including schizophrenia, epilepsy, Parkinson's disease and substance use disorder. Cerevel Therapeutics is advancing its current research and development programs while exploring new modalities through internal research efforts, external collaborations or potential acquisitions.

Cerevel Therapeutics Holdings (STU:673) Headlines

No Headlines